Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | DRD2 | P14416 | 2/20 | 0.34 |
| ▸ | DRD4 | P21917 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6855685 | 0.66 | REN (0.33) | — | |
| SCHEMBL6857190 | 0.63 | TSHR (0.31) | TSHR | |
| SCHEMBL8890381 | 0.61 | NPC1 (0.49) | TSHRALDH1A1KDM4EPOLBHDAC1 | |
| SCHEMBL24117314 | 0.61 | PDE4A (0.46) | HTTPDE4D | |
| SCHEMBL6857189 | 0.59 | REN (0.38) | — | |
| SCHEMBL8892297 | 0.59 | RXRA (0.54) | TSHRHTTPDE4DHDAC1HDAC6 | |
| SCHEMBL3655669 | 0.58 | IDO1 (0.53) | NPSR1 | |
| SCHEMBL2931109 | 0.57 | REN (0.73) | — | |
| SCHEMBL11028601 | 0.57 | EHMT2 (0.42) | TSHRKDM4EPOLBPDE4D | |
| SCHEMBL8890420 | 0.57 | HIF1A (0.55) | TSHRALDH1A1KDM4EHTTHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092706-A1 | Process for the manufacture of enantiomerically pure aryloctanoic acids as aliskiren | CarboDesign LLC (US) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092706-A1 | Process for the manufacture of enantiomerically pure aryloctanoic acids as aliskiren | REN, CYP51A1, CYP2A7 | TSHR 3077/4885DRD2 2890/4885DRD4 2359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.